We argue that low Q1 sales are no problem. We have historically learnt that BD revenues (concentrate) may show quarterly volatility and the company pointed out that in-market sales trends have been strong in Q4/25-Q1/26. We instead focus on deal flow, which has remained weak in recent years. There was nothing new on that front in Q1, we think, although the company confirmed confidence and high interest across key therapeutic fields.
LÄS MER
